Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral antimicrobials for UTIs cited as "good model" for OTC switch by McNeil's Korberly.

This article was originally published in The Tan Sheet

Executive Summary

ORAL ANTIMICROBIALS FOR UTIs CITED AS "GOOD MODEL" FOR OTC SWITCH by McNeil Consumer Medical New Product Development Director Barbara Korberly, PharmD, at the recent National Managed Health Care Congress in Washington, D.C. Speaking on potential Rx-to-OTC switches, Korberly noted that treatment of urinary tract infections is a "good model" for an OTC switch because there are "17 mil. [physician's] office visits per year" that could be avoided, the drugs are "highly specific" and do not have "many side effects," and "for a short course of therapy, it's relatively inexpensive compared to" a physician's office visit "and/or getting a culture."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel